[{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Carotuximab","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"jCyte","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"jCell","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Santen Pharmaceutical","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.25,"dosageForm":"Intravitreal Injection","sponsorNew":"Santen Pharmaceutical \/ Santen Pharmaceutical ","highestDevelopmentStatusID":"8","companyTruncated":"Santen Pharmaceutical \/ Santen Pharmaceutical "},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Levofloxacin","moa":"DNA gyrase","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"RVL Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Oxymetazoline Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.089999999999999997,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ RVL Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ RVL Pharmaceuticals"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.14999999999999999,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Santen Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Alcon Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"Netarsudil","moa":"Rho-associated protein kinase","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.17000000000000001,"dosageForm":"Ophthalmic Solution","sponsorNew":"Santen Pharmaceutical \/ Santen","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Santen"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"Calcineurin","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Emulsion","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"UBE Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Omidenepag Isopropyl","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Santen Pharmaceutical \/ UBE Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ UBE Corporation"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Glycerine","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oil\/Drops","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tafluprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Sydnexis","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Atropine Sulfate","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Santen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Santen Pharmaceutical \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Visiox Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Omidenepag Isopropyl","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Visiox Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Visiox Pharmaceuticals"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Fluorometholone Acetate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santen Pharmaceutical \/ Harrow Health","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Harrow Health"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Harrow","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Fluorometholone Acetate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santen Pharmaceutical \/ Harrow","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Harrow"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Latanoprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tafluprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Santen Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tafluprost","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Santen Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Santen Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Santen Pharmaceutical \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Santen Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Catiolanze® is a preservative-free latanoprost 50μg/mL eye drop cationic emulsion. The active substance latanoprost, a prostaglandin F2α analogue, is a selective proteinoid FP receptor agonist which reduces the IOP by increasing the outflow of aqueous...

                          Brand Name : Catiolanze

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 17, 2023

                          Lead Product(s) : Latanoprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationo...

                          Brand Name : Flarex

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 24, 2023

                          Lead Product(s) : Fluorometholone Acetate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Harrow

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the agreement, Visiox gain rights to product manufacturing, commercialization, and sales of Omlonti (omidenepag isopropyl), an eye drop for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

                          Brand Name : Omlonti

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 18, 2023

                          Lead Product(s) : Omidenepag Isopropyl

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Visiox Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationo...

                          Brand Name : Flarex

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 17, 2023

                          Lead Product(s) : Fluorometholone Acetate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Harrow

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          05

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : STN1011101, a preservative-free combination eye drop of tafluprost 0.0015% and timolol 0.5%. It is being developed for lowering intraocular pressure of patients with open-angle glaucoma or ocular hypertension.

                          Brand Name : STN1011101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 08, 2023

                          Lead Product(s) : Tafluprost,Timolol Maleate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Cationorm® Plus (glycerol) is a sterile, preservative-free, artificial tear containing the novel Novasorb® technology. As the only artificial tear that uses positive cationic emulsion to hold hydration in place, it protects, hydrates and lubricates the...

                          Brand Name : Cationorm Plus

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 06, 2022

                          Lead Product(s) : Glycerine,Tyloxapol API,Detalan

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension...

                          Brand Name : Omlonti

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 26, 2022

                          Lead Product(s) : Omidenepag Isopropyl

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : UBE Corporation

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Verkazia (cyclosporine) is a prescription-only, uniquely formulated cationic nanoemulsion that provides improved ocular bioavailability of cyclosporine, which has been shown to be effective in the management of VKC.

                          Brand Name : Verkazia

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          May 02, 2022

                          Lead Product(s) : Cyclosporine

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Santen will be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Rho...

                          Brand Name : Rhopressa

                          Molecule Type : Small molecule

                          Upfront Cash : $88.0 million

                          December 07, 2021

                          Lead Product(s) : Netarsudil

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Recipient : Alcon Inc

                          Deal Size : $168.0 million

                          Deal Type : Expanded Collaboration

                          blank

                          10

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The agreement aims for SYD-101, Sydnexis’ investigational proprietary low dose atropine sulfate formulation, for Europe, Middle East and Africa (EMEA), is currently undergoing a phase III clinical trial, the STAAR study, in Europe and the US to help co...

                          Brand Name : SYD-101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 10, 2021

                          Lead Product(s) : Atropine Sulfate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase III

                          Recipient : Sydnexis

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank